

**Country: Australia**

**Organisation: National Health and Medical Research Council (NHMRC)**

This document contains **information on specific requirements** for researchers applying for funding by the funding organisation indicated above. To make sure that your application is fully in line with the specific requirements and to receive latest information, please contact the respective **national contact person**. Not fulfilling the requirements may lead to ineligibility of the application.

### Contact

|                                |  |
|--------------------------------|--|
| <b>National contact person</b> | Dr Adam Chapman<br>National Health and Medical Research Council (NHMRC)<br>Email: <a href="mailto:dementia.research@nhmrc.gov.au">dementia.research@nhmrc.gov.au</a> |
|--------------------------------|--|

### Eligibility

|                                |  |
|--------------------------------|--|
| <b>Eligible Institutions</b>   | <p>Institutions must be a <a href="#">NHMRC Administering Institution</a> to be eligible to receive and administer NHMRC funding.</p> <p>Applications for NHMRC funding are subject to the general eligibility requirements as set out in the NHMRC-European Union Joint Programme - Novel imaging and brain stimulation methods and technologies related to Neurodegenerative Diseases 2020 Guidelines when available on <a href="#">GrantConnect</a> and <a href="#">NHMRC Funding Agreement</a>. Applicants should read all relevant reference material.</p>  |
| <b>Additional requirements</b> | <p>NHMRC will only fund applications with a key focus on Alzheimer’s disease or other dementias. Applying for funding with any other focus under this call will not be supported through the NHMRC -European Union Joint Programme - Novel imaging and brain stimulation methods and technologies related to Neurodegenerative Diseases 2020. However, Australian researchers who have other sources of funding are not restricted to this focus.</p> <p>Additional guidance on this requirement: Dementia is the outward and visible manifestation of a number of diseases resulting in deficits in memory, thinking, behaviour and ability to perform everyday activities. Alzheimer’s disease is the most common cause, but there are many other causes of dementia (e.g. vascular dementia, dementia with Lewy bodies, frontotemporal dementia, etc.) and other symptoms. There are many other conditions which are associated with dementia. In this context, dementia can be a feature of Parkinson’s.</p> |

|  |  |
|--|--|
|  | <p>For this call, a project will fall within scope for funding by NHMRC if the project explicitly addresses dementia, or if the focus is on dementia as part of the broader manifestations of a neurodegenerative disorder. For example, a project that examines the phenotypic variation seen in Parkinson's would not be within scope, but a project that examines Parkinson's-related dementia would be within scope.</p> <p>Applicants from Australia intending to apply for funding via NHMRC should notify the national contact point to signal an intention to join a consortium, via <a href="mailto:dementia.research@nhmrc.gov.au">dementia.research@nhmrc.gov.au</a>.</p> <p>Australian applicants should also refer to the <a href="#">NHMRC website</a> for specific documentation for this Grant Opportunity when it becomes available. NHMRC funding is subject to governmental approval processes.</p> |
|--|--|

## Budget

|   |  |
|---|--|
| <b>Total earmarked national budget</b>  | €1 million (approx. AUD\$1.6 million)  |
| <b>Anticipated no. of funded groups</b> | Three (3)  |
| <b>Budget restrictions</b>              | <p>Please refer to the NHMRC-European Union Joint Programme - Novel imaging and brain stimulation methods and technologies related to Neurodegenerative Diseases 2020 Guidelines when available on <a href="#">GrantConnect</a></p> <p>Each Australian team may apply for up to three years of funding up to a maximum of \$AUD0.5 million per team.</p> |
| <b>Eligible costs</b>                   | <p>Please refer to:</p> <ul style="list-style-type: none"> <li>Section 5 of the NHMRC-European Union Joint Programme - Novel imaging and brain stimulation methods and technologies related to Neurodegenerative Diseases 2020 Guidelines when available on <a href="#">GrantConnect</a></li> <li><a href="#">NHMRC Funding Agreement</a></li> </ul>     |